查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球性传播疾病检测市场（2019-2029）：规模、份额、趋势分析、机会、预测——按疾病、地点、设备、地区分类
市场调查报告书
商品编码
1186467

全球性传播疾病检测市场（2019-2029）：规模、份额、趋势分析、机会、预测——按疾病、地点、设备、地区分类

Sexually Transmitted Disease Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Disease ; By Location ; By Device ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 200 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球性传播疾病检测市场规模预计到 2022 年将达到 914 亿美元，在 2023-2029 年的预测期内以 6.2% 的复合年增长率增长，到 2029 年将达到 1355 亿美元。 推动市场的关键因素包括 STD 患病率和发病率的增加、国家筛查计划的增加以及对全球 STD 检测报销的支持增加。 然而，与就诊 STD 专科诊所的患者相关的社会耻辱感以及对偏远地区 STD 感染患者的强有力保护预计将阻碍分析期间的市场增长。

本报告研究了全球性病检测市场，提供了市场概况、市场驱动因素和限制因素分析、市场机会、细分市场分析、竞争格局、COVID-19 它提供了系统信息，包括 19 种影响、概况重点公司等。

内容

第一章研究框架

第 2 章执行摘要

第 3 章全球性病检测市场：洞察

  • 行业价值链分析
  • DROC 分析
    • 增长动力
      • 全球范围内性传播疾病的高流行率和发病率不断上升
      • 实施国家筛查计划
      • 支持 STD 检测报销
    • 约束因素
      • 与就诊 STD 诊所的患者相关的社会污名化
      • 为偏远地区的性病感染者提供强有力的保护
    • 机会
      • 减少去政府诊所的次数
      • 世界各地的国家筛选计划
      • 新兴经济体中技术和 POC 测试提供商的利基机会
    • 任务
      • 严格监管
  • 技术进步/最新发展
  • 监管框架
  • 波特的五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争激烈程度

第 4 章。全球性病检测市场：概述

  • 市场规模和预测（2019-2029 年）
    • 按金额
  • 市场份额和预测
    • 按疾病分类
      • 衣原体
      • 梅毒
      • 淋病
      • 超单纯形病毒
      • 人类免疫缺陷病毒
      • 硬下疳
      • 其他
    • 按位置
      • 实验室
      • 护理点 (POC)
    • 按设备
      • 实验设备
      • 护理点 (POC) 设备
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区
      • 拉丁美洲
      • 中东和非洲

第五章北美性病检测市场

  • 市场规模和预测（2019-2029 年）
    • 按金额
  • 市场份额和预测
    • 按疾病分类
    • 按位置
    • 按设备
    • 按国家
      • 美国
      • 加拿大

第 6 章欧洲性病检测市场

  • 市场规模和预测（2019-2029 年）
    • 按金额
  • 市场份额和预测
    • 按疾病分类
    • 按位置
    • 按设备
    • 按国家
      • 德国
      • 英国
      • 意大利
      • 法国
      • 西班牙
      • 荷兰
      • 其他欧洲

第 7 章亚太地区性病检测市场

  • 市场规模和预测（2019-2029 年）
    • 按金额
  • 市场份额和预测
    • 按疾病分类
    • 按位置
    • 按设备
    • 按国家
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳大利亚和新西兰
      • 印度尼西亚
      • 马来西亚
      • 新加坡
      • 菲律宾
      • 越南
      • 亚太其他地区

第 8 章拉丁美洲的性病检测市场

  • 市场规模和预测（2019-2029 年）
    • 按金额
  • 市场份额和预测
    • 按疾病分类
    • 按位置
    • 按设备
    • 按国家
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 哥伦比亚
      • 其他拉丁美洲

第 9 章中东和非洲的性传播疾病检测市场

  • 市场规模和预测（2019-2029 年）
    • 按金额
  • 市场份额和预测
    • 按疾病分类
    • 按位置
    • 按设备
    • 按国家
      • 沙特阿拉伯
      • 阿拉伯联合酋长国
      • 卡塔尔
      • 科威特
      • 南非
      • 尼日利亚
      • 阿尔及利亚
      • 其他中东和非洲地区

第10章竞争格局

  • 主要公司及其产品列表
  • 全球性病检测公司的市场份额分析（2022 年）
  • 按运营参数进行竞争性基准测试
  • 重大战略发展（合併、收购、合作等）

第 11 章全球性病检测市场：COVID-19 的影响

第12章公司概况（公司概况、财务矩阵、竞争格局、关键人才、主要竞争对手、联繫人、战略展望、SWOT分析）

  • Abbott Laboratories
  • BioMerieux, Inc.
  • Becton Dickinson Company
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Hologic, Inc.
  • Diasorin Molecular LLC
  • Roche Holding AG
  • Orasure Technologies, Inc.,
  • Thermo Fisher Scientific Inc.
  • AccuBioTech Co. Ltd.
  • AdvaCare Pharma
  • BIOGENIX Inc. Pvt. Ltd.
  • CTK Biotech Inc.
  • Everlywell Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • 其他有影响力的公司

第 13 章关键战略建议

第 14 章研究方法论

简介目录
Product Code: BWC23024

Global Sexually Transmitted Disease Testing Market Size Expands to Cross USD 135.5 Billion by 2029.

Global sexually transmitted disease (STD) testing market is flourishing because of an increasing prevalence and rising incidences of STDs, growing establishment of national screening programs, and rising support for STD testing reimbursements across the globe.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global sexually transmitted disease (STD) testing market size at USD 91.4 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global sexually transmitted disease testing market size to grow at a steady CAGR of 6.2% reaching a value of USD 135.5 billion by 2029. Major factors for the expansion of global sexually transmitted disease testing market include increasing public awareness and patient education, global rise in the incidence of sexually transmitted illnesses, increasing patient awareness through education campaigns, and a surge in government activities. The prevalence and incidence of sexually transmitted illnesses have increased significantly during the previous decade. As the frequency of sexually transmitted illnesses increases, countries worldwide are focused on the deployment of national screening programs to expand the coverage of sexually transmitted disease diagnosis. Also, the payment regulations for services related to sexually transmitted diseases have been favorable. Technology advancements and developments in the diagnosis of STDs are also projected to boost market expansion. Increased national screening program implementation to increase sexually transmitted disease diagnosis coverage will also boost the demand for STDs testing. These reasons are considerably driving the growth of the global sexually transmitted diseases testing market. However, social stigma associated with patients visiting specialized STD clinics and huge protection of patients infected with STDs in remotes areas are anticipated to hinder the market growth during the period in analysis.

Global Sexually Transmitted Disease Testing Market - Overview

Sexual health testing is a collection of diverse tests and procedures used to diagnose and detect sexually transmitted illnesses, such as Chlamydia, Gonorrhea, Trichomonas, HIV, HSV, HCV, HPV, and others. For sexual health testing, four major types of testing are employed, including Culture/Isolation of Organisms, Molecular Test, Immunology Assay, and others. HIV can be diagnosed using one of three HIV tests: antibody testing, antigen/antibody tests, and nucleic acid tests (NAT). STD prevalence and incidence have risen considerably in the recent decade. As the prevalence of sexually transmitted illnesses rises, nations around the world are focusing on developing nationwide screening programs to increase the adoption of sexually transmitted disease diagnostics coverage. Reimbursement regulations for diagnostic services for sexually transmitted diseases have been useful. These factors are significantly contributing to the growth of the global sexually transmitted diseases diagnostics market.

Impact of COVID-19 on Global Sexually Transmitted Disease Testing Market

COVID-19 adversely affected the STD (sexually transmitted disease) testing market. Due to disruptions in healthcare and STD testing facilities, the CDC (Centers for Disease Control and Prevention) observed a decline in STD testing during the early months of COVID-19. Few members may have unwittingly disseminated the virus due to inadequate testing and diagnosis. As a result, even though the transmission of STDs rose during the pandemic, the market value declined due to the decrease in testing. STD testing surged once the lockdown and travel ban were lifted, and the market is projected to boost the expansion of market growth.

Global Sexually Transmitted Disease Testing Market - By Location

Based on location, global sexually transmitted disease testing market is bifurcated in Laboratory and Point of Care (PoC). In 2022, the laboratory testing segment had a higher market share, but PoC testing is expected to rise at a faster rate in the years ahead. Laboratory testing includes commercial/private labs and public health labs. Laboratory testing is a time-consuming but more exact procedure that involves commercial/private labs as well as public health labs. Likewise, the PoC segment includes testing kits, is faster, the results may be less exact. However, bedside testing or mobile testing that allows for rapid healthcare provision for patients is capturing market share. There has been a major transition from traditional laboratory tests to rapid and easy point of care tests, due to the benefits provided by point of care testing equipment.

Competitive Landscape:

Major players operating in global sexually transmitted disease testing market include: Abbott Laboratories, BioMerieux, Inc., Becton Dickinson Company, Danaher Corporation, Bio-Rad Laboratories, Inc., Hologic, Inc., Diasorin Molecular LLC, Roche Holding AG, Orasure Technologies, Inc., Thermo Fisher Scientific Inc., AccuBioTech Co. Ltd., AdvaCare Pharma, BIOGENIX Inc. Pvt. Ltd., CTK Biotech Inc., Everlywell Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, and Merck and Co. Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Sexually Transmitted Disease Testing Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Sexually Transmitted Disease Testing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Sexually Transmitted Disease Testing Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. High Prevalence & Rise in Incidences of STD across the Globe
      • 3.2.1.2. Implementation of National Screening Programs
      • 3.2.1.3. Supporting Reimbursement of STDs Testing
    • 3.2.2. Restraints
      • 3.2.2.1. Social Stigma Associated with Patients Visiting Specialized STD Clinics
      • 3.2.2.2. Huge Protection of Patients Infected with STDs in Remotes Areas
    • 3.2.3. Opportunities
      • 3.2.3.1. Decrease In Number of Visits to Government Clinics
      • 3.2.3.2. National Screening Programs Across the Globe
      • 3.2.3.3. Niche Opportunities for Technology and POC Test Providers in an Emerging Economy
    • 3.2.4. Challenges
      • 3.2.4.1. Stringent Regulations
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Sexually Transmitted Disease Testing Market Overview

  • 4.1. Market Size & Forecast by Value, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Disease
      • 4.2.1.1. Chlamydia
      • 4.2.1.2. Syphilis
      • 4.2.1.3. Gonorrhoea
      • 4.2.1.4. Hyper Simplex Virus
      • 4.2.1.5. Human Immunodeficiency Virus
      • 4.2.1.6. Chancroid
      • 4.2.1.7. Others
    • 4.2.2. By Location
      • 4.2.2.1. Laboratory
      • 4.2.2.1.1. Commercial/Private Labs
      • 4.2.2.1.2. Public Health Labs
      • 4.2.2.2. Point of Care (POC)
    • 4.2.3. By Device
      • 4.2.3.1. Laboratory Devices
      • 4.2.3.1.1. Thermal Cyclers PCR
      • 4.2.3.1.2. Lateral Flow Readers- Immune Chromatographic Arrays
      • 4.2.3.1.3. Flow Cytometers
      • 4.2.3.1.4. Differential Light Scattering Machines
      • 4.2.3.1.5. Absorbance Micro Plate Reader- Enzyme- Linked Immunosorbent Assay (ELISA)
      • 4.2.3.1.6. Others
      • 4.2.3.2. Point of Care (POC) Devices
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific
      • 4.2.4.4. Latin America
      • 4.2.4.5. Middle East and Africa

5. North America Sexually Transmitted Disease Testing Market

  • 5.1. Market Size & Forecast by Value, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease
    • 5.2.2. By Location
    • 5.2.3. By Device
    • 5.2.4. By Country
      • 5.2.4.1. US
      • 5.2.4.1.1. By Disease
      • 5.2.4.1.2. By Location
      • 5.2.4.1.3. By Device
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Disease
      • 5.2.4.2.2. By Location
      • 5.2.4.2.3. By Device

6. Europe Sexually Transmitted Disease Testing Market

  • 6.1. Market Size & Forecast by Value, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease
    • 6.2.2. By Location
    • 6.2.3. By Device
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Disease
      • 6.2.4.1.2. By Location
      • 6.2.4.1.3. By Device
      • 6.2.4.2. UK
      • 6.2.4.2.1. By Disease
      • 6.2.4.2.2. By Location
      • 6.2.4.2.3. By Device
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Disease
      • 6.2.4.3.2. By Location
      • 6.2.4.3.3. By Device
      • 6.2.4.4. France
      • 6.2.4.4.1. By Disease
      • 6.2.4.4.2. By Location
      • 6.2.4.4.3. By Device
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Disease
      • 6.2.4.5.2. By Location
      • 6.2.4.5.3. By Device
      • 6.2.4.6. The Netherlands
      • 6.2.4.6.1. By Disease
      • 6.2.4.6.2. By Location
      • 6.2.4.6.3. By Device
      • 6.2.4.7. Rest of Europe
      • 6.2.4.7.1. By Disease
      • 6.2.4.7.2. By Location
      • 6.2.4.7.3. By Device

7. Asia-Pacific Sexually Transmitted Disease Testing Market

  • 7.1. Market Size & Forecast by Value, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease
    • 7.2.2. By Location
    • 7.2.3. By Device
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Disease
      • 7.2.4.1.2. By Location
      • 7.2.4.1.3. By Device
      • 7.2.4.2. India
      • 7.2.4.2.1. By Disease
      • 7.2.4.2.2. By Location
      • 7.2.4.2.3. By Device
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Disease
      • 7.2.4.3.2. By Location
      • 7.2.4.3.3. By Device
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Disease
      • 7.2.4.4.2. By Location
      • 7.2.4.4.3. By Device
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Disease
      • 7.2.4.5.2. By Location
      • 7.2.4.5.3. By Device
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Disease
      • 7.2.4.6.2. By Location
      • 7.2.4.6.3. By Device
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Disease
      • 7.2.4.7.2. By Location
      • 7.2.4.7.3. By Device
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Disease
      • 7.2.4.8.2. By Location
      • 7.2.4.8.3. By Device
      • 7.2.4.9. Philippines
      • 7.2.4.9.1. By Disease
      • 7.2.4.9.2. By Location
      • 7.2.4.9.3. By Device
      • 7.2.4.10. Vietnam
      • 7.2.4.10.1. By Disease
      • 7.2.4.10.2. By Location
      • 7.2.4.10.3. By Device
      • 7.2.4.11. Rest of APAC
      • 7.2.4.11.1. By Disease
      • 7.2.4.11.2. By Location
      • 7.2.4.11.3. By Device

8. Latin America Sexually Transmitted Disease Testing Market

  • 8.1. Market Size & Forecast by Value, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease
    • 8.2.2. By Location
    • 8.2.3. By Device
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Disease
      • 8.2.4.1.2. By Location
      • 8.2.4.1.3. By Device
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Disease
      • 8.2.4.2.2. By Location
      • 8.2.4.2.3. By Device
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Disease
      • 8.2.4.3.2. By Location
      • 8.2.4.3.3. By Device
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Disease
      • 8.2.4.4.2. By Location
      • 8.2.4.4.3. By Device
      • 8.2.4.5. Colombia
      • 8.2.4.5.1. By Disease
      • 8.2.4.5.2. By Location
      • 8.2.4.5.3. By Device
      • 8.2.4.6. Rest of LATAM
      • 8.2.4.6.1. By Disease
      • 8.2.4.6.2. By Location
      • 8.2.4.6.3. By Device

9. Middle East & Africa Sexually Transmitted Disease Testing Market

  • 9.1. Market Size & Forecast by Value, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease
    • 9.2.2. By Location
    • 9.2.3. By Device
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Disease
      • 9.2.4.1.2. By Location
      • 9.2.4.1.3. By Device
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Disease
      • 9.2.4.2.2. By Location
      • 9.2.4.2.3. By Device
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Disease
      • 9.2.4.3.2. By Location
      • 9.2.4.3.3. By Device
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Disease
      • 9.2.4.4.2. By Location
      • 9.2.4.4.3. By Device
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Disease
      • 9.2.4.5.2. By Location
      • 9.2.4.5.3. By Device
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Disease
      • 9.2.4.6.2. By Location
      • 9.2.4.6.3. By Device
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Disease
      • 9.2.4.7.2. By Location
      • 9.2.4.7.3. By Device
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Disease
      • 9.2.4.8.2. By Location
      • 9.2.4.8.3. By Device

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Sexually Transmitted Disease Testing Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Sexually Transmitted Disease Testing Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 12.1. Abbott Laboratories
  • 12.2. BioMerieux, Inc.
  • 12.3. Becton Dickinson Company
  • 12.4. Danaher Corporation
  • 12.5. Bio-Rad Laboratories, Inc.
  • 12.6. Hologic, Inc.
  • 12.7. Diasorin Molecular LLC
  • 12.8. Roche Holding AG
  • 12.9. Orasure Technologies, Inc.,
  • 12.10. Thermo Fisher Scientific Inc.
  • 12.11. AccuBioTech Co. Ltd.
  • 12.12. AdvaCare Pharma
  • 12.13. BIOGENIX Inc. Pvt. Ltd.
  • 12.14. CTK Biotech Inc.
  • 12.15. Everlywell Inc.
  • 12.16. F. Hoffmann La Roche Ltd.
  • 12.17. Gilead Sciences Inc.
  • 12.18. GlaxoSmithKline Plc
  • 12.19. Merck and Co. Inc.
  • 12.20. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumption & Limitation